Sodium-glucose cotransporter 2 inhibitors do not increase the risk of fractures in real-world clinical practice in Korea: A national observational cohort study.

ABSTRACT:

Aims/introduction

This study aimed to determine whether sodium-glucose cotransporter 2 inhibitors (SGLT2i) were related to increased fracture risk in adults with type 2 diabetes compared with dipeptidyl peptidase-4 inhibitors (DPP-4i).

Materials and methods

Between 1 May 2016 and 31 December 2018, we carried out a new-user cohort study using the Korean National Health Insurance Service database. Propensity score matching was carried out on 478,826 new users of an SGLT2i or DPP-4i. After propensity score matching on >80 covariates, 84,460 individuals were initiated on SGLT2i or DPP-4i, with 42,230 individuals in each treatment group. The time to first fracture event was compared between the SGLT2i and DPP-4i groups using Cox proportional hazards models, and the results are re

SUBMITTER: Ha KH 

PROVIDER: S-EPMC9153829 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature